— Know what they know.
Not Investment Advice

HMTXF OTC

Hemostemix Inc
1W: -13.1% 1M: -20.9% 3M: +16.1% YTD: -30.7% 1Y: -38.1% 3Y: -51.8% 5Y: -80.4%
$0.04
-0.00 (-0.08%)
 
Weekly Expected Move ±7.4%
$0 $0 $0 $0 $0
OTC · Healthcare · Biotechnology · Tech Score Sell · Power 35 · $8.6M mcap · 155M float · 0.0064% daily turnover · Short 94% of daily vol

Balance Sheet Trends

Total Assets
$992K +216.1% ▲
5Y CAGR: +56.9%
Total Liabilities
$8M +6.6% ▲
5Y CAGR: +14.6%
Shareholders Equity
-$7M +2.3% ▲
Cash & Investments
$706K +354.1% ▲
5Y CAGR: +96.5%
Total Debt
$5M +14.2% ▲
5Y CAGR: +19.1%
Net Debt
$4M +1.6% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2020FY2021FY2022FY2023FY2024
— Assets —
Cash$258K$219K$136K$155K$706K
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$258K$219K$136K$155K$706K
Net Receivables$2M$343K$139K$25K$230K
Inventory$0-$343K$0$0$0
Other Current Assets$0$343K$0$0$0
Total Current Assets$2M$562K$465K$314K$992K
Property, Plant & Equip.$2K$901$406$183$83
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$0$0$0$0$0
Total Non-Current Assets$2K$902$407$184$84
Total Assets$2M$563K$465K$314K$992K
— Liabilities —
Accounts Payable$2M$3M$3M$3M$3M
Short-Term Debt$175K$0$0$0$0
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$1M$1M$3K$0$0
Total Current Liabilities$3M$4M$3M$3M$3M
Long-Term Debt$0$1M$4M$4M$5M
Other Non-Current Liab.$0$0$487K$0$0
Total Non-Current Liabilities$0$1M$5M$5M$5M
Total Liabilities$3M$6M$7M$8M$8M
— Equity —
Common Stock$38M$39M$41M$42M$44M
Retained Earnings-$49M-$56M-$61M-$63M-$66M
Accumulated OCI$2M$2M$3M$1M$2M
Total Stockholders Equity-$1M-$5M-$7M-$7M-$7M
Total Liabilities & Equity$2M$563K$465K$314K$992K
— Key Metrics —
Total Debt$175K$1M$4M$4M$5M
Net Debt-$83K$1M$4M$4M$4M
Total Investments$0$0$0$0$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms